Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant

Clinical Transplantation

Volumn 28, Issue 6, 2014, Pages 722-727

  Kwo, Paul Y ^a   Ghabril, Marwan ^a   Lacerda, Marco A ^a   Joseph Tector, Alfred ^a   Fridell, Jonathan A ^a   Vianna, Rodrigo ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Direct acting antiviral agents; Drug drug interactions; Hepatitis C; Orthotopic liver transplant

Indexed keywords

CYCLOSPORIN A; DIURETIC AGENT; ELTROMBOPAG; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; TACROLIMUS; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ANORECTAL DISEASE; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BLOOD TRANSFUSION; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHROCYTE CONCENTRATE; FEMALE; HEPATITIS C; HUMAN; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RASH; RECURRENT INFECTION; RETREATMENT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; HEPACIVIRUS; ISOLATION AND PURIFICATION; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECOMBINANT PROTEINS; RECURRENCE; RETREATMENT; RIBAVIRIN; RISK FACTORS; VIRAL LOAD;

EID: 84901854480     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12372     Document Type: Article

References (18)

1. Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 2004: 4: 7.
2. Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003: 7: 585.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002: 122: 889.
4. Wiesner RH, Sorrell M, Villamil F. International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003: 9: S1.
5. Abdelmalek MF, Firpi RJ, Soldevila-Pico C et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004: 10: 199.
6. Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997: 112: 575.
7. Gordon FD, Kwo P, Ghalib R et al. Peginterferon-alpha-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation. J Clin Gastroenterol 2012: 46: 700.
8. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C. Med Lett Drugs Ther 2011: 53: 57.
9. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011: 364: 1195.
10. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011: 364: 2405.
11. Garg V, van Heeswijk R, Eun Lee J, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011: 54: 20.
12. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011: 364: 2417.
13. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011: 364: 1207.
14. Hezode C, Dorival C, Zoulim F et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC). J Hepatol 2012;56(Suppl 2): S4.
15. McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009: 361: 580.
16. Werner CR, Egetemeyr DP, Lauer UM et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012: 18: 1464.
17. Coilly A, Roche B, Dumortier J et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014: 60: 78.
18. Mantry PS, Mubarak A, Weinstein JS et al. 837 Early virologic response in patients with HCV recurrence after liver transplant treated with triple therapy: a single center experience. Gastroenterology 2012;142:S-931.